Our client base includes organisations across the pharmaceutical development cycle, patient organisations and governmental health institutions
Pharmaceutical companies (HQ and affiliate levels)
The Danish Clinical Registries: A National Quality Improvement Programme (RKKP)
The Swedish Association of local Authorities and Regions (SALAR/SKL)
World Health Organisation (WHO)
ApHER is experienced in documenting the value of innovative technologies for the health care system. We offer strategic advice on medical device market access
Medical Device Manufacturers
Health care system technology implementation
ApHER is engaged in projects and studies dealing with sustainable business models and environmental policies
European Commission, DG Climate
STOA, European Parliament
Clinical expertise across therapeutic areas
Partnerships & Innovation
Innovating science by growing our academic network
As an independent research organisation we ensure our services contribute to increased interaction between research, industry and the society at large. We do so in a transparent manner in accordance with national and international legal frameworks. As partner of the ENCePP network we continuously align our research methods with developments in the field of European and international pharmacoepidemiological standards.
We continue to develop our technology further to encompass a broader range of aspects, including comparative health technology assessments related to various types of interventions.
For each specific project we build multidisciplinary teams. This is to ensure trustworthy and sustainable solutions from both a scientific and commercial perspective. We offer all relevant competencies and a unique approach to investigate epidemiological, economic and clinical aspects of health care. Our multidisciplinary teams are the backbone in our independent research, which delivers peer reviewed documentation.
We continuously seek partnerships with international research groups and relevant organizations to further develop our multidisciplinary approach and include more therapy areas. The team members will be identified from the extensive network of academic and industry professionals who contemplate our partners and affiliations’ partners.
Combining medical expertise and analytical excellence
In developing a new intervention it is important to understand its dynamic impact on the disease.This enables assessment of true health economic consequences over time. Based on epidemiological methods ApHER has deviced such a model, the “BOX model” which has proven its global applicability. With this model the value of any given intervention is estimated by its contribution to the parameters in the intervention.
Annual input to the patient population (new patients per year) is calculated with outset in the population at risk of developing a given disease. From this we deduct the annual output from the patient population (deaths and recoveries, as relevant). Adding input, and subtracting output, from the prevalence at the beginning of the year yields the prevalence ultimo the year. By repeating this accountance year by year the trends over time in input and output rates as well as the resulting prevalence is obtained. The patient population may be stratified in sub-groups. For example, treatment status, so that internal transitions between the various states is monitored over time
PROM is short for Patient Reported Outcome Measure. PROM is an umbrella term covering quality of life (QOL) measures. It also includes other outcomes measures where patients’ views are presented. PROM includes measures on symptoms of diseases, level of functioning, as well as health related QOL. Measures of ‘patient satisfaction’ with a given care can also be included in PROM.
ApHER develops PROMs to specific disease or medications to monitor the results of a treatment in a regions, a hospital or a department over time. This can be used for benchmarking purposes and quality management. A survey may be used to systematically detect how a patient group experience the effect of existing or new treatments.
At ApHER, we have a process-oriented approach to project management. We include our clients throughout the entire process as we strive to serve our client’s interests.
Even though our focus is on solutions to the client’s scientific, financial, medical or environmental challenges, there is a need for qualified project managers to plan and execute the work. To meet our clients’ expectations, we have a team of highly competent project managers to ensure that project goals are achieved within given constraints.
The project manager will initiate, plan, execute, control and end the work of the project team to meet the clients’ defined success criteria and ensure that the scope, time, quality and budget meets the clients’ expectations. The project management team at ApHER includes, among others, health economists, pharmacists and medical doctors.
The Box Model
The Box Model accounts for the patient population
Complications contribute significantly to the cost of chronic diseases and is relevant to monitor dynamics
No complications (status 0), Minor complications (status 1) and Major complications (status 2)
A patient of any status group can either move up one step (e.g. 0 to 1) or die
The number of prevalent patients for each status group at base versus intervention scenario is modeled based on epidemiology